Kairos Pharma appoints Rahul Singhvi as director, replacing Rosemary Mazanet

Kairos Pharma, LTD.

Dr. Rosemary Mazanet resigned from board effective upon appointment of new independent director; not due to disagreement.
Dr. Rahul Singhvi appointed director effective Dec 10, 2024; will serve on audit committee, chair compensation and nominating/corporate governance committees.
Singhvi is cofounder of Resilience, former CEO of Novavax (NVAX), former COO of Takeda's Vaccine business.
Singhvi receives $50K annual cash fee and $50K in RSUs vesting over three years under 2023 Equity Incentive Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.